Patricia Myers

Cooley advised CareJourney, a preeminent provider of clinically relevant healthcare data and artificial intelligence-powered analytics and insights, on its acquisition by Arcadia, a top data platform for healthcare.

Cooley advised Perceptive Advisors, a top healthcare investment firm, and its affiliates, including Perceptive Discovery Fund, on its definitive merger agreement with Vapotherm, a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, and listed as VAPO on the over-the-counter quotation exchange (OTCQX).

Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.

Cooley advised ChrysCapital, a top India-focused private equity firm, on the close of its oversubscribed $700 million continuation fund and general partner-led secondary transaction to purchase and sell its stake in the National Stock Exchange of India (NSE) with two of the world’s leading secondary fund investors. The landmark transaction is the largest of its kind in India and ranks among the largest in the Asia-Pacific region.

Cooley advised Tenet Medicines, a development-stage private biotechnology company, on its definitive agreement to be acquired by Eliem Therapeutics, a biotech company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems.